HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NSAID/Breast Cancer Study Joins Inconsistent Body Of Data On Relationship

This article was originally published in The Tan Sheet

Executive Summary

Long-term, daily aspirin and ibuprofen use are linked to an increased risk of breast cancer in a recent epidemiologic study by Sarah Marshall, University of Southern California, et al.

You may also be interested in...

Aspirin Benefit In Breast Cancer Risk Linked To Hormone Receptivity – JAMA

A potential chemopreventive effect of aspirin and other NSAIDs on breast cancer may be linked to the hormone receptor status of the tumor, researchers reported in the May 26 Journal of the American Medical Association

Regular aspirin use fails to reduce risk of breast cancer -- NCI Journal.

REGULAR ASPIRIN USE DOES NOT REDUCE THE RISK OF BREAST CANCER, Kathleen Egan et al. concluded in a prospective study published in the July 17 Journal of the National Cancer Institute. The Harvard researchers examined aspirin use and cancer incidence among women who participated in the 1980-1992 Nurses' Health Study.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts